Archives
-
Perphenazine: D2 Antagonist Research Workflows
2026-09-20
Perphenazine combines dopamine D2 receptor antagonism with measurable mitochondrial and host-defense phenotypes, making it useful for both neuropharmacology and translational immunology workflows. This guide connects receptor profiling, mitochondria-mediated cell death induction, macrophage antibacterial assays, and practical troubleshooting while keeping cytotoxicity and pleiotropic signaling under control.
-
Clozapine N-oxide (CNO) Assay Workflows
2026-09-19
A practical, evidence-based guide to using Clozapine N-oxide (CNO), SKU A3317, in chemogenetic and cell-based workflows. It addresses assay compatibility, stock preparation, control design, data interpretation, and product-selection criteria for more reproducible neuroscience research.
-
Clozapine N-oxide (CNO) for Circuit Research
2026-09-18
Clozapine N-oxide (CNO) gives researchers reversible, cell-selective control of DREADD-expressing circuits without implanted stimulation hardware. This workflow-oriented guide shows how to use it alongside 40 Hz sensory entrainment assays to distinguish circuit necessity, sufficiency, and downstream effects in epilepsy and broader neuroscience research.
-
EZ Cap™ EGFP mRNA: Assay Reliability
2026-09-18
Learn how EZ Cap™ EGFP mRNA (SKU R1002) can function as a controlled Cap 1 EGFP mRNA reporter input when delivery, viability, and cytotoxicity results are difficult to interpret. This scenario-based guide connects practical assay controls with published dendritic-cell electroporation findings while clearly separating evidence from workflow recommendations.
-
Auditory Activity Sustains Neurogenesis and Cognition
2026-09-17
The reference study identifies a causal auditory-to-hippocampal pathway in which cochlear outer hair cell loss weakens PnCvGluT2 input to locus coeruleus norepinephrine neurons, reducing norepinephrine support for adult neurogenesis and cognition. Projection-specific stimulation restores both neurogenic and cognitive outcomes, providing a circuit-level explanation for how hearing loss can affect brain function.
-
CDC42 Polarity Controls Intestinal Stem Cell Fate
2026-09-17
Zhang and colleagues show that CDC42-dependent epithelial polarity controls the intestinal stem cell to transit-amplifying cell transition through a YAP/TAZ–Ereg–EGFR–mTOR cascade, rather than through canonical Wnt signaling. Their genetic and pharmacological experiments distinguish restoration of crypt proliferation and cell-fate balance from restoration of epithelial polarity.
-
7ACC2: A Monocarboxylate Transporter 1 Inhibitor
2026-09-16
7ACC2 is a potent monocarboxylate transporter 1 inhibitor for dissecting lactate flux, mitochondrial pyruvate handling, and tumor radiosensitization. This workflow-oriented guide shows how to connect transport assays with metabolic and immunosuppressive tumor-microenvironment readouts without overinterpreting cross-cell effects.
-
PF-573228: A Causal Probe of FAK Signaling
2026-09-16
PF-573228 is a potent FAK inhibitor for dissecting how adhesion and matrix stiffness regulate cell behavior. This article translates the LAMB1–FAK–MEK1/2 findings in dentinogenesis into a rigorous assay strategy spanning mechanotransduction, angiogenesis, and cancer biology.
-
Perphenazine in Host-Directed Antibacterial Research
2026-09-15
Explore how Perphenazine, a dopamine D2 receptor antagonist, can support mechanistic studies spanning neuropharmacology and host-directed antibacterial research. This guide emphasizes receptor-aware assay design, macrophage defense biology, and interpretation of ROS, autophagy, and mitochondrial endpoints.
-
CDK4/6–BET Synergy in Pancreatic Cancer Wnt Signaling
2026-09-15
The 2025 reference study shows that palbociclib can suppress pancreatic tumor-cell proliferation while paradoxically increasing migration, invasion, and epithelial-to-mesenchymal transition. Its central innovation is the use of BET inhibition to counter this adaptive response through GSK3β-mediated Wnt/β-catenin and TGF-β/Smad pathway regulation, producing stronger antitumor activity in vitro and in an orthotopic model.
-
BI 2536: A Better Way to Read PLK1 Inhibition
2026-09-14
BI 2536 is a selective PLK1 inhibitor for dissecting mitotic arrest, growth suppression, and apoptosis in cancer models. This article applies a two-axis assay framework to improve interpretation of BI 2536 responses from cultured cells to tumor xenograft models.
-
Ruxolitinib JAK1/2 Research Workflows
2026-09-14
Build reproducible Ruxolitinib assays by connecting phospho-STAT readouts, progenitor-cell growth, and immune-cell profiling. This practical workflow also adapts the reference study’s multi-readout design without confusing TLR4 biology with direct JAK1/2 inhibition.
-
Prestained Protein Marker for LARP1 Blot Workflows
2026-09-13
Use a Triple color protein ladder to connect ribosome-fractionation experiments with confident SDS-PAGE sizing, transfer checks, and fluorescent imaging. This workflow shows how an EDTA-free marker supports LARP1 research without overstating what a molecular-weight standard can prove.
-
BBB Permeability Modeling with Lysosomal Correction
2026-09-12
The 2025 Drug Delivery study developed a high-throughput surrogate blood-brain barrier model by pairing LLC-PK1-MOCK and LLC-PK1-MDR1 cells with bidirectional Transwell transport measurements. Its lysosomal-trapping correction improved interpretation of low-recovery compounds and strengthened the relationship between in vitro permeability and in vivo unbound brain distribution.
-
L-Threonine: Metabolism and ALP Assays
2026-09-11
L-Threonine is an essential proteinogenic amino acid that links protein biosynthesis with central carbon metabolism. Its role in alkaline phosphatase research is interpretive rather than pharmacological: the cited metal-free nanozyme assay measures ALP through pyrophosphate hydrolysis, not through L-Threonine inhibition.